Not actual patients with Fabry disease.
Not actual patients with Fabry disease.

Keep your Fabry patients moving forward with Galafold

For adults with confirmed Fabry disease and an amenable GLA variant

Galafold—the first oral precision medicine for Fabry disease

Galafold is a small-molecule alpha-Gal A pharmacological chaperone that reversibly binds to the active site of alpha-Gal A and stabilizes the protein.1,2

Galafold restores the normal pathway for trafficking amenable alpha-Gal A to the lysosome.2

Galafold has a large apparent volume of distribution of approximately 89 L (range: 77 to 133 L) at steady state,2 suggesting it is well distributed into tissues.1,3

Galafold reduced disease substrate (GL-3) in kidney interstitial capillaries (KIC) over 6 months.2*

The most common adverse drug reactions reported with Galafold (≥10%) are headache, nasopharyngitis, urinary tract infection, nausea, and pyrexia.2

the first patient was treated in a clinical trial4
patients worldwide are being treated with Galafold as of August 20214
adherence for patients on Galafold4
Mean change in average number of GL-3 inclusions per KIC from Baseline to Month 6 was -0.04 (95% CI: -1.94, 0.26; n=25) with Galafold treatment vs -0.03 (95% CI: -1.00, 1.69; n=20) with placebo.2
Data on file – August 2021. Calculated based on prescription shipment data.4
Please see Important Safety Information for Galafold below.

A distinct approach to the treatment of Fabry disease

See how Galafold works

Watch this video to learn more about the mechanism of action for Galafold.

Identify whether your patient's GLA variant is amenable to treatment with Galafold

Starting with your patient's GLA genotype, you can determine whether the GLA variant is amenable in 1 of 3 ways:

The Galafold Full Prescribing Information includes a list of GLA variants that have been identified as amenable to Galafold.

Check amenability on this website to determine whether a specific GLA variant has been listed as amenable in the Full Prescribing Information.

For answers to questions about amenability, you can also contact Amicus Medical Information at 1-877-4-AMICUS or

Download the Galafold Patient Referral Form

Start a Patient